TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will be included in the case of:~  * Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2~ * Participants must be 18 years of age or older~ * Have ascites of malignant disease~ * Have symptoms related to ascites~ * Ascites Index above 0.05 (AI ˃ 0.05)~ * Be an English speaking patient or have an interpreter available~ * Be able to understand and comply with all study requirements and the implications of off-label use of intraperitoneal Bevacizumab~ * Have had at least two paracentesis within the last 4 weeks~Exclusion Criteria:~* Patients will be excluded in the case of:~  * Ascites due to non-malignant cause~ * Concurrent treatment with systemic chemotherapy that has a realistic chance of controlling the ascites~ * Concurrent treatment with intraperitoneal Bevacizumab~ * life expectancy of less than 2 weeks~ * A history of bowel perforation or fistula~ * Symptoms or signs suggestive of bacterial peritonitis~ * Child's C cirrhosis~ * Uncontrolled hypertension~ * Surgery within 28 days of catheter treatment~ * Evidence of coagulopathy~ * Symptoms suggestive of bowel obstruction~ * Major surgery, open biopsy or significant traumatic injury within seven (7) days of first study drug--including neurosurgery.~ * Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements.~ * Concurrent severe illness such as active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements~ * Patients who are pregnant or lactating (females of childbearing potential must have a negative pregnancy test prior to participation)~ * Patients with pre-existing 3 + or greater urine dipstick reading proteinuria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eligible patients requiring paracentesis for symptom control (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Intermittent Tiotropium in Early Childhood Wheezing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Children at the age of 6 to 35 months.~2. Two to four physician-confirmed episodes of wheeze and/or shortness of breath.~3. Parents/legal representatives with sufficient written and spoken skills in Finnish language.~Exclusion Criteria:~1. Birth before 36th week of gestation.~2. Suspected/diagnosed chronic parenchymal lung disease or a structural airway defect, or a history of thoracotomy with pulmonary resection.~3. A history of congenital or acquired heart disease, including any unstable or life-threatening cardiac arrhythmia.~4. Constipation with a need of regular medication, or a diagnosed/suspected structural defect in the gastrointestinal tract.~5. A history of malignancy, or other significant chronic disorder, disease, or defect.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: f

Study Arms:
- Tiotropium Bromide & Salbutamol (Type: EXPERIMENTAL): Inhaled Tiotropium Bromide 5 µg once a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
- Fluticasone Propionate & Salbutamol (Type: ACTIVE_COMPARATOR): Inhaled Fluticasone Propionate 125 µg twice a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
- Salbutamol (Type: ACTIVE_COMPARATOR): Inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Overactive Bladder Education

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of overactive bladder~* able and willing to participate and consent~* age \>17 years, \<90 years~* female sex~Exclusion Criteria:~* male sex~* patients who do not have a diagnosis of overactive bladder~* age \<18 years, \>89 years~* unable or unwilling to participate~* patients who are already being treated for overactive bladder~* patients who are planning surgical intervention for pelvic organ prolapse prior to treatment of overactive bladder~* patients who are planning surgical intervention for stress urinary incontinence prior to treatment of overactive bladder~* pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Standard Care Group (Type: NO_INTERVENTION): In this group, subjects will receive standard counseling regarding Overactive Bladder.
- Care Plan Group (Type: EXPERIMENTAL): In this group, subjects will receive counseling regarding Overactive Bladder using a printed Overactive Bladder Plan of Care information sheet.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: TDCS and Aphasia Therapy in the Acute Phase After Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with mild-moderate aphasia (Token Test Score between 7 and 40)~* Inclusion in the first few days after stroke (acute phase)~* Age 18 - 85 years~* Being right-handed~* Mothertongue: Dutch~* Able to undergo functional and specific linguistic testing and therapy in the acute phase following stroke~* Imaging (CT or MRI) prior to inclusion (standard of care)~* Signed Informed Consent~Exclusion Criteria:~* History of other diseases of the central nervous system, psychological disorders and (developmental) speech and or language disorders~* Serious non-linguistic, cognitive disorders (as documented in the patients' medical history and inquired in anamneses)~* Prior brain surgery~* Excessive use of alcohol or drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Aphasia therapy and tDCS (Type: ACTIVE_COMPARATOR): None
- Aphasia therapy and sham-tDCS (Type: SHAM_COMPARATOR): None
- Standard of care and sham-tDCS (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients between the ages of 18 and 75 years undergoing non-urgent, elective spinal fusion at Massachusetts General Hospital who are admitted to the neurosurgery floor from the operating room~Exclusion Criteria:~* Patients who are taken to the operating room from another inpatient floor or service (already hospitalized prior to surgery)~* Patients with evidence of bowel obstruction~* Patients unable to take oral medications by mouth or by enteric feeding tube (gastrostomy or jejunostomy)~* Patients with a documented or potential allergy or adverse reaction to Movantik (naloxegol) from outpatient use~* Patients currently taking Movantik (naloxegol) in the outpatient setting~* Patients with a preoperative diagnosis of irritable bowel syndrome (IBS) obtained via Rome III questionnaire on screening~* Patients with disruptions to the blood-brain barrier (eg, multiple sclerosis, recent brain injury, Alzheimer's disease, and uncontrolled epilepsy)~* Patients with a history of cancer.~* Patients concomitantly using strong CYP3A4 inhibitors (eg, clarithromycin, ketoconazole), strong CYP3A4 inducers and other opioid antagonists.~* Patients with severe hepatic impairment.~* Patients with a previous history of or risk of bowel perforation.~* Patients with a post-op regional anesthetic technique employed like a continuous epidural or spinal.~* Patients for which local anesthetics will be placed in the wound.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MOVANTIK™ (naloxegol) (Type: EXPERIMENTAL): Subjects in the treatment group will be administered MOVANTIK™ (naloxegol) 25 mg tablet or placebo once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing). Subjects with renal impairments (creatine clearance rate of less than 60 mL/min) will receive a 12.5 mg dose tablet of naloxegol in place of the 25 mg dose as advised by FDA guidelines. For patients who are unable to swallow the tablet whole, the tablet can be crushed and given orally or administered via nasogastric tube.
- Sugar pill (Type: PLACEBO_COMPARATOR): Matching placebo consists of an inert mixture supplied by AstraZeneca in identical-appearing tablets. Subjects in the placebo group will be administered a placebo tablet once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Two Protocols for Corporal Decolonization in Patients Colonized by Methicillin Resistant Staphylococcus Aureus (MRSA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- MRSA infected or colonized Patients~Exclusion Criteria:~Patients whose condition or treatment interferes with the proper implementation of the proposed protocols, such as:~* Patients admitted to the ICU~* Patients undergoing resuscitation~* Immobilized patients-avoiding their complete hygiene~* Patients carrying nasogastric tube~* Patients with tracheostomy and / or assisted mechanical ventilation~* Patients who are unable, neither they nor their representatives, to give valid informed consent.~* Patients whose discharged is planned before completing protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chlorhexidine + Mupirocin (Type: ACTIVE_COMPARATOR): Will be treated with the protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07, as shown listed in Table 4. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days).
- Prontoderm (Type: EXPERIMENTAL): Will be treated with the protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Well-being and Stress Control After Colorectal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patient undergoing colorectal cancer surgery~* Regulated surgery~* With or without radiation treatment and / or preoperative chemotherapy.~* Patient benefiting from a social protection scheme~Exclusion criteria:~-- Limitation of linguistic or cognitive abilities interfering with the understanding of the study protocol~* Absence of the consent form of the study~* Emergency surgery~* Stomy closure~* Patient diagnosed psychotic.~* Patient with psychiatric disorder left to the discretion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C-Bien (Type: EXPERIMENTAL): None
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PTH Analog Type II Odontoid Fracture

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 50 years or older at time of consent \[treatment subjects\] or age 50 years or older at time of fracture (historical control subjects)~* Anderson and D'Alonzo type II dens fracture identified on cervical spine CT, with or without a C1 ring injury. Type II dens fractures are defined as involving the area of the dens between the inferior aspect of the anterior C1 ring and not extending into the superior articular facets of C2 \[all subjects\]~* Fracture is deemed amenable to non-operative treatment by treating fellowship trained spine surgeon \[treatment subjects only\]~* Fracture occurred within the 3 weeks before consent \[treatment subjects only\]~* Report of \>=12 months of amenorrhea within the last year if the patient is female treatment subjects only\]~* Fracture injury occurred within 10 years before consent \[historical control subjects only\]~* The patient completed 12 (+/-1) weeks of hard collar immobilization \[historical control subjects only\]~Exclusion Criteria:~* Personal history of radiation therapy or accidental environmental exposure \[treatment subjects only\]~* Personal history of osteosarcoma \[treatment subjects only\]~* Personal history of Paget's disease \[treatment subjects only\]~* Personal history of bone metastases or skeletal malignancy \[treatment subjects only\]~* Hereditary disorders predisposing to osteosarcoma \[treatment subjects only\]~* Prior teriparatide or abaloparatide use \[treatment subjects only\]~* Any history of prior teriparatide or abaloparatide use \[historical control subjects only\]~* Use of denosumab within the past year \[all subjects\]~* Psychological impairment that precludes following hard collar immobilization recommendations \[treatment subjects only\]~* Ineligible based on history of active or recurrent kidney stones, Comprehensive Metabolic Panel, PTH, Phos results to be determined on a case-by-case basis by an endocrinologist on the study team \[treatment subjects only\]

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Daily self-administered injection of 80 mcg abaloparatide (8 weeks) + hard collar immobilization (12 weeks)
- Historical control group (Type: ACTIVE_COMPARATOR): Patients who received only 12 weeks of hard collar immobilization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 or ≤ 75 years~* Patients with rhegmatogenous retinal detachment that require vitrectomy surgery~Exclusion Criteria:~* Previous pars plana vitrectomy in the affected eye~* Positive for Hepatitis B surface antigen or HIV antibodies, or history of Hepatitis B/HIV~* Pregnant or breast-feeding~* Liver disease or abnormal AST/ALT~* Renal impairment (Creatinine clearance \< 50)~* Diabetes with current use of insulin~* Anemia (Hemoglobin \<13.2 g/dL (male) or \< 11.6 g/dL (female))~* Unwilling to hold concurrent use of sorbitol or sorbitol-containing medications or products while taking study medication(including, but not limited to: blackberries, raspberries, strawberries, stone fruits, apples, avocados, sugar-free items such as chewing gum, hard candies, snack bars, frozen desserts, and chocolates, liquid and capsule/caplet analgesics, cough/cold/flu syrup, liquid and capsule/caplet pseudoephedrine, chewable antacid tablets, liquid and capsule allergy medications, motion sickness and nausea medications)~* Current use of trimethoprim-sulfamethoxazole~* Pancreatitis or history of pancreatitis~* Uncontrolled blood pressure (\> 160 mm Hg systolic or \>100 mm Hg diastolic) within the last 3 months, or current use of more than one anti-hypertensive medication~* History of stroke, myocardial infarction, or congestive heart failure~* Current vitreous hemorrhage that obscures view of retinal details~* Patients with a shallow anterior chamber or in whom anterior chamber paracentesis is considered unsafe

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lamivudine (Type: EXPERIMENTAL): Lamivudine 300mg PO once daily for three days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily for three days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects 18 years of age or older~* Female subjects 18 years of age or older of non-child bearing potential defined by a serum follicle stimulating hormone (FSH) level ≥ 25.8 mIU/ml or by a confirmed clinical history of sterility (e.g. hysterectomy)~* Renal transplantation performed two years or more before inclusion~* Stable renal transplant function as determined by physician~* Actinic keratosis, one or multiple, of the trunk and/or extremities, non-hypertrophic non-hyperkeratotic based on clinical judgment within an area of 100 cm2 total (several areas adding up to 100 cm2 permissible)~* Signed Informed Consent after oral and written explanation of the study protocol~Exclusion Criteria:~* contraindications on ethical grounds such as inability to give informed consent~* women of child-bearing potential, women who are pregnant or breast feeding~* other clinically significant concomitant disease (e.g. hepatic dysfunction, cardiovascular disease, etc) at the investigator's discretion~* known or suspected non-compliance, drug or alcohol abuse~* enrolment into a clinical trial within last 4 weeks~* prior treatment with ingenol mebutate gel~* prior local/topical treatments in the treatment area within 2 weeks of trial entry:~  * Dermabrasion, chemical peeling, laser treatment, cryotherapy or surgery~ * Imiquimod, diclofenac, 5-Fluorouracil (5-FU), topical corticosteroids, topical retinoids, treatment with ultraviolet B (UVB) or photodynamic treatment (PDT)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ingenol mebutate 500 ucg (Type: EXPERIMENTAL): active arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Low or intermediate-1 risk myelodysplastic syndromes by International Prognostic Scoring System (IPSS) criteria~  * IPSS score \< 1.5~* Requiring transfusion of 2 units of red blood cells at least once a month (four weeks prior to accrual on study)~* High levels of endogenous epoetin alfa (i.e., \> 200 mU/mL)~  * Unlikely to respond to epoetin alfa, or has a documented clinical non-response to epoetin alfa (at a dose of ≥ 40,000 U weekly) or darbepoetin alfa (at a dose \> 200 mcg every other week) (i.e., \< 2 g/dL increase in hemoglobin and no decrease in transfusion requirements after at least 4 weeks of treatment)~* No chronic myelomonocytic leukemia~PATIENT CHARACTERISTICS:~* ECOG Performance Status of 0-2~* Liver enzymes (AST and ALT) and total bilirubin ≤ 2 times upper limit of normal~* Serum creatinine ≤ 2 times upper limits of normal~* No clinically significant anemia due to iron, B12, or folate deficiencies; autoimmune or hereditary hemolysis; or gastrointestinal bleeding~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other serious or poorly controlled medical condition that could be exacerbated by or complicate compliance with study therapy~PRIOR CONCURRENT THERAPY:~* At least 4 weeks since prior treatment (including growth factors)~* No chronic use (\> 2 weeks) of physiologic doses of a corticosteroid agent (dose equivalent to \> 10 mg/day of prednisone) within 28 days of the first day of study drug~* No concurrent use of another investigational agent~* No concurrent therapy with any cytotoxic drugs, steroids, or growth factors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAD001 (everolimus) (Type: EXPERIMENTAL): RAD001 (everolimus) at 10mg/day with Bone marrow aspirate/biopsy and other laboratory biomarker analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues